History

Nandrolone was developed by Organon, and Deca-Durabolin (nandrolone decanoate, NDA 13-132) was approved in the US on October 5, 1962, with a surviving labeled indication for the management of the anemia of renal insufficiency. Organon notified FDA in a letter dated May 21, 2002 that it had stopped marketing the brand in the US, and the product moved to the Orange Book Discontinued Drug Product List; FDA's 2010 Federal Register determination found it was not withdrawn for reasons of safety or effectiveness. Generic nandrolone decanoate remains a legally prescribable Schedule III product per current DailyMed labeling.

Nandrolone, best known by the brand name Deca-Durabolin, is a synthetic anabolic-androgenic steroid (AAS) — chemically 19-nortestosterone, the “nor” analogue of testosterone. It is not a peptide and not a SARM. It has a genuine, high-quality human evidence base for building lean mass in catabolic illness, and it carries a structurally lower liver-injury risk than oral 17α-alkylated steroids — but it remains an exogenous androgen with strong hormonal suppression, characteristic sexual side effects, and the cardiovascular risks common to chronic AAS use.

What it is

Nandrolone is 19-nortestosterone (chemically 17β-hydroxyestr-4-en-3-one), differing from testosterone by removal of the C19 methyl group. It is the parent compound of the “19-nor” AAS family. Clinically it is used as oil-based, injectable 17β-esters — most commonly nandrolone decanoate (Deca-Durabolin) and the shorter-acting nandrolone phenylpropionate (Durabolin). The ester is cleaved in vivo to release free nandrolone and changes only the release kinetics, not the underlying pharmacology.

Crucially, nandrolone is not 17α-alkylated — that is the structural feature responsible for the marked hepatotoxicity of oral AAS such as stanozolol, oxymetholone, or methyltestosterone. Mechanistically, nandrolone is an androgen-receptor (AR) agonist that binds the AR with relatively high affinity and is described in classic rodent assays as having a favorable anabolic-to-androgenic dissociation (though those ratios are model-dependent and not precise clinical predictors). Two features distinguish it from testosterone:

Reduced androgenicity in androgen-target tissue. Where testosterone is amplified to the more potent DHT by 5α-reductase, nandrolone is instead reduced to 5α-dihydronandrolone (DHN), which has weaker AR affinity and potency. This is why nandrolone is relatively less androgenic in tissues rich in 5α-reductase (scalp, skin, prostate).
Progestogenic activity. Nandrolone binds the progesterone receptor with roughly 22% of the affinity of progesterone — more than testosterone does — which contributes to characteristic side effects (loss of libido and erectile complaints colloquially called “deca dick,” and a contribution to gynecomastia). It is also aromatized to estrogen at a substantially lower rate than testosterone, so estrogenic effects per AR effect are lower — though not zero, and the progestogenic activity adds to gynecomastia risk.

The claims

Medically, nandrolone is used (historically and currently) for the anemia of chronic kidney disease/renal insufficiency, where it raises hemoglobin and red-cell mass, and it has been studied for wasting and cachexia (HIV, dialysis) and as an anabolic adjunct. Newer agents — erythropoiesis-stimulating agents for anemia and modern wasting therapies — have largely displaced it in routine practice.

In performance and bodybuilding settings it is used illicitly to increase lean mass and is valued as a “joint comfort” adjunct, with its slow ester release and comparatively lower androgenic and hepatic profile (versus orals) cited as advantages. This profile is a reference, not a how-to; no dosing, cycle, ester-timing, or post-cycle protocols are provided.

What the evidence actually shows

The human evidence that nandrolone increases lean/muscle mass is consistent and high quality:

Dialysis patients (RCT). Johansen, Mulligan, and Schambelan (JAMA, 1999) ran a randomized, double-blind, placebo-controlled trial in hemodialysis patients. Nandrolone significantly increased lean body mass (mean change +4.5 kg vs +1.9 kg with placebo over 6 months; P=.005) with functional improvement (PMID 10208142).
HIV-associated wasting, men. Storer et al. (J Clin Endocrinol Metab, 2005) ran a placebo-controlled RCT with open-label rhGH as an active reference. Nandrolone increased lean body mass (+1.6 kg vs +0.4 kg placebo; rhGH +2.5 kg) — superior to placebo and not significantly different from the FDA-approved rhGH regimen (PMID 15914526).
HIV-associated wasting, women. Mulligan et al. (Arch Intern Med, 2005), a randomized, double-blind, placebo-controlled multicenter trial in HIV-infected women with weight loss, found increases in weight (+4.6 kg) and lean body mass (+3.5 kg; P<.001) (PMID 15767536).
Recent synthesis (2026). Prokopidis et al. (J Cachexia Sarcopenia Muscle, 2026; DOI 10.1002/jcsm.70276), a systematic review and meta-analysis of RCTs to April 2025, found nandrolone decanoate significantly increased lean soft tissue (+1.59 kg; 95% CI 1.06–2.13) but showed no significant effect on fat mass, handgrip strength, or knee-extension strength, with inconsistent bone-density outcomes (only total proximal femur BMD improved). GRADE certainty was low, and the authors concluded the gains are modest with limited functional benefit, favoring non-pharmacological strategies.

Bottom line on effect: the evidence for increased lean/muscle mass is consistent; the evidence that this translates into meaningful strength, functional, or bone gains is weaker and inconsistent.

Legal and regulatory status

In the United States, nandrolone is a Schedule III controlled substance under the Controlled Substances Act. The Anabolic Steroids Control Act of 1990 placed AAS in Schedule III, and the Anabolic Steroid Control Act of 2004 (signed October 22, 2004) expanded and clarified the statutory list. Nandrolone is explicitly named in the current definition at 21 U.S.C. § 802(41)(A)(xxxiv): “nandrolone (17β-hydroxyestr-4-en-3-one).” It is legal only with a valid prescription; non-medical distribution or possession is a federal offense. Generic nandrolone decanoate remains a legally prescribable Schedule III product, with a labeled indication for anemia of renal disease.

For context (these are not nandrolone facts): clenbuterol is neither FDA-approved for human use nor a scheduled controlled substance, and recombinant hGH is not a CSA-controlled substance — its non-medical distribution is criminalized separately under 21 U.S.C. § 333(e), not via AAS scheduling.

In sport, nandrolone is a prohibited anabolic agent under the WADA Prohibited List, class S1.1 (anabolic androgenic steroids), prohibited at all times (in- and out-of-competition). It is detected in urine via its principal metabolite 19-norandrosterone (19-NA). Because trace 19-NA can arise endogenously, WADA applies a decision/reporting limit of 2 ng/mL, the same for both male and female athletes (the female threshold was lowered from 5 to 2 ng/mL in 2004). A concentration above this limit triggers confirmatory analysis by GC/C/IRMS to establish exogenous origin; in initial testing, a screening level around 2.5 ng/mL serves as an alarm point that prompts further confirmatory analysis — it is a screening trigger, not the reporting threshold.

Safety

Nandrolone’s structure spares it the liver risk of oral steroids, but it is still an exogenous androgen with real, well-documented harms.

HPTA suppression / infertility: It strongly suppresses the hypothalamic-pituitary-testicular axis (LH/FSH and endogenous testosterone), reducing spermatogenesis with potential infertility. Its progestogenic activity makes suppression and recovery particularly problematic, and suppression can be prolonged.
Sexual dysfunction (“deca dick”): Low endogenous testosterone plus progestogenic activity commonly causes loss of libido and erectile dysfunction.
Lipids and cardiovascular: AAS generally lower HDL and can raise LDL and blood pressure, and promote adverse cardiac remodeling (LV hypertrophy) and atherosclerosis with chronic use. Nandrolone’s lipid effect is generally milder than that of 17α-alkylated orals — one study (Glazer & Suchman, Metabolism, 1994; PMID 8121303) found no significant change in HDL/LDL with weekly nandrolone decanoate over 6 weeks — but it is not lipid-neutral, and chronic supraphysiologic AAS use carries real cardiovascular risk.
Hepatotoxicity: Low for nandrolone, because it is not 17α-alkylated; it lacks the cholestasis, peliosis hepatis, nodular regeneration, hepatic adenoma, and hepatocellular carcinoma risks characteristic of oral 17α-alkylated AAS. Per NIH LiverTox, those liver injuries are tied to the 17α-alkylated androgens, whereas esterified/parenteral testosterone-type androgens carry much lower risk (mild enzyme changes possible).
Erythrocytosis: It raises hemoglobin and hematocrit (the basis of its anemia indication), but supratherapeutic use can cause polycythemia and thrombotic risk.
Gynecomastia / estrogenic-progestogenic effects: Despite low aromatization, gynecomastia and water retention occur, driven partly by progestogenic activity.
Virilization (women): Voice deepening, hirsutism, clitoromegaly, and menstrual disruption — some changes are irreversible.
Other: Acne, mood and behavioral changes, possible effects on glucose, injection-related risks, and the risks of contaminated or mislabeled underground product.

Bottom line

Nandrolone has a genuine, high-quality human evidence base — but the consistent finding is increased lean mass in catabolic-illness populations (dialysis, HIV wasting), not validated strength, functional, or bone benefit, and not performance enhancement in healthy people, where rigorous evidence is lacking. It is a Schedule III prescription anabolic steroid, banned at all times in sport, and carries real androgenic, hormonal-suppression, and cardiovascular risks. Its lower liver risk versus oral steroids does not make it “safe.”

Evidence grade: Strong human.

Nandrolone (Deca-Durabolin)